• Guy-Charles Fanneau de La Horie has more than 20 years of experience in the pharmaceutical and biotechnology industries. Prior to joining Pherecydes Pharma, he held several international management positions, namely at Schering-Plough, Biogen and IDM, in Europe and the United States. Most recently, Guy-Charles was the CEO of PathoQuest, a company specialized in pathogen identification. Between 2006 and 2013, he was CEO of Neovacs, where he led the company’s IPO in 2010.

    Prior to that, he spent eight years at Biogen, where he created and managed the subsidiaries in France and Benelux, managed the sales force in the United States and held European responsibilities. Guy-Charles is a graduate of the Ecole Nationale Vétérinaire de Lyon and the INSEAD graduate business school.

  • Philippe Rousseau has more than 20 years of experience in the biotechnology industry in both private and listed companies. Before joining Pherecydes Pharma, he held several positions in Finance and General Management in Europe and the United States. More recently, Philippe was Deputy CEO of ABCDx in Geneva (diagnosis of brain lesions), was in charge of the development of the US market for CYTOO (company specialized in muscular diseases) and was CFO of Vivalis (Valneva). Between 2003 and 2009, he was Chief Financial Officer, then Acting CEO and a member of the Executive Board of ExonHit Therapeutics, which he listed on the stock market in 2005.

    Previously, after beginning his career in banking and strategic consulting, Philippe joined the biotech industry as IR Director, then VP of Finance at Genset in 1998. Philippe is a graduate of the HEC business school.

  • Cindy is a microbiologist, expert in bacteriology. She obtained a PhD at the Pasteur Institute (Paris) in the antibiotic resistance, virulence and genetic diversity of Klebsiella. She has also worked on other major pathogens in human clinical practice, such as listeria and staphylococcus aureus.

    Prior to joining Pherecydes Pharma, Cindy developed new phage display methods and acquired substantial knowledge of bacteriophage biology and genomics. Her international experience (UMC Utrecht, Netherlands) has led her to manage R&D collaborations with industrial potential.

  • Frédérique, Doctor in Pharmacy and Engineer in Biotechnology, is a graduate of the Universities Blaise Pascal Clermont II, Montpellier I and Polytech Clermont-Ferrand. She has some twenty years of experience mainly as Quality Director in large pharmaceutical groups such as MSD, Europhartech, Carbogen Amcis and 4D Pharma PLC. She is the founder of 5QBD, a firm specialized in Quality and Business Development for biotech companies.

  • Brigitte Palestro is a graduate of the Lyon I and Paris XII Faculties of Medicine and the author of various scientific publications. She has more than 24 years of experience in the biotechnology industry. Before joining Pherecydes Pharma, she was a Medical Manager in well-known pharmaceutical groups such as Pfizer, Roche and Ipsen. She has also worked in medical consulting.

Supervisory Board


  • Didier Hoch
    Chairman - Independent
  • Maryvonne Hiance
    Vice-Chairwoman - Independente
  • Franck Lescure
    Permanent representative of Elaia Partners
  • Leila Nicolas
    Permanent representative of Go Capital
  • Guy Rigaud
  • Robert Sebbag
  • Eric Leire


  • Delphine Dinard

Know more about our partnerships